Soleno Therapeutics, Inc. Earnings Recaps
Q3 2025
Nov 5, 2025
Soleno Therapeutics delivered exceptional third quarter results, with net revenues more than doubling to $66 million, culminating in a positive net income of $26 million as VYKAT XR establishes itself in the market as a crucial treatment for Prader-Willi syndrome (PWS).
Key takeaways
- Achieved over 764 active patients on VYKAT XR six months post-launch, signaling strong market adoption.
- Total net revenue surged more than 100% from Q2, highlighting robust growth momentum.
- Despite a temporary disruption from a short seller report, patient engagement initiatives led to a rebound in therapy initiation as awareness and education advance.
- Ongoing preparations for a marketing authorization application in the EU could significantly expand the addressable market for VYKAT XR.
- Discontinuation rates remain below expectations, reflecting manageable safety concerns and effective patient management strategies.